Clinical trials: Schizophrenia Spectrum Disorders
Psychotic Disorders, Veterans
Impact of VVV Group for Veterans With SMI
Veterans with Serious Mental Illness (SMI) struggle with social integration - participation in work, housing, and citizenship - due to symptoms, stigma, and psychosocial challenges.
- Trial name
- VVV (NCT05562674)
- Testing
- Veteran Voices and Visions
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
The primary objective of this study was to continue to provide aripiprazole intramuscular (IM) depot treatment (400 milligrams [mg] or 300 mg) to participants with schizophrenia completing the 52-week, open-label safety and…
- Trial name
- ASPIRE (NCT01129882)
- Testing
- Aripiprazole
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 709 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Feasibility Electrical Stimulation Study for Visual Hallucinations
The visual system has increasingly been recognized as an important site of injury in patients with schizophrenia and other psychoses.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT04870710
- Testing
- transcranial electrical stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
- Trial name
- NCT01658150
- Testing
- isradipine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Schizoaffective Disorder
Virtual Reality Job Interview Training in Severe Mental Illness
This is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (VR-JIT). Northwestern University is partnering with Thresholds Inc.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT03049813
- Testing
- Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Michigan
Schizophrenia, Schizoaffective Disorder
Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters.
- Trial name
- NCT01578486
- Testing
- salsalate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02832037
- Testing
- BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3
- Where
- 81 sites in United States, Austria and 9 more
- Volunteers
- 509 people
- Sponsor
- Boehringer Ingelheim
Cognition in Schizophrenia
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving.
- Trial name
- NCT00628394
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Psychotic Disorders, Psychosis Nos/Other
Psychosis Screening in Juvenile Justice
This study will investigate the occurrence of psychosis-spectrum disorders among youth in the Juvenile Justice System and track mental health referrals for these youth in Phase 1, a standard care condition.
- Trial name
- JJ-Psychosis (NCT03583073)
- Testing
- Enhanced Referral/Linkage to Care, Standard Care
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Brown University
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Psychotic Disorders, Depressive Disorder, Major
Treatment of Schizoaffective Disorder Using Mifepristone
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
- Conditions
- Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
- Trial name
- NCT00725270
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Schizophrenia
Once-Daily Asenapine for Schizophrenia
The investigators propose to explore: 1. the acceptance by patients of once versus twice daily dosing with asenapine, 2. the acceptance by staff of once versus twice daily dosing with asenapine, and 3.
- Trial name
- NCT01549041
- Testing
- Asenapine 10 mg daily in the evening, Asenapine 5 mg twice daily
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Schizophrenia
Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension
This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously…
- Trial name
- PRISMA-3_OLE (NCT03870880)
- Testing
- Risperidone ISM 75 mg, Risperidone ISM 100 mg
- Where
- 24 sites in United States, Ukraine
- Volunteers
- 215 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
- Trial name
- NCT02634346
- Testing
- ALK3831, Olanzapine
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 403 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
The primary aims of this study are to assess tolerability of ziprasidone dose escalation to 320 milligrams per day (mg/d) compared to continued standard treatment (placebo) as measured by the Side Effect Checklist, Simpson Angus…
- Trial name
- HDZ (NCT00403546)
- Testing
- Ziprasidone 80-160 mg/d, Ziprasidone 160 mg/d
- Where
- 9 sites in United States
- Volunteers
- 131 people
- Sponsor
- Donald C. Goff, MD
Schizophrenia
The Effects of Nicotine on Cognition in Schizophrenia
Patients with schizophrenia have a variety cognitive deficits and nicotine has been shown to normalize some of these deficits. The purpose of this study is to investigate the effects of nicotine on cognition in schizophrenia.We…
- Trial name
- NCT00383747
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
CAE for Poorly Adherent Individuals With Schizophrenia
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
- Trial name
- CAE-S (NCT06061952)
- Testing
- Customized Adherence Enhancement for Schizophrenia (CAE-S), Enhanced Treatment as Usual (eTAU)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.
- Trial name
- NCT01626885
- Testing
- MP-214
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Tanabe Pharma Corporation